ascopubs.org

First results of an open-label, single arm phase II trial investigating the efficacy and safety of trifluridine/tipiracil combined with irinotecan as a second line therapy in ...

Genomic and outcome analysis of recurrent versus de novo metastatic pancreatic ductal adenocarcinoma (PDAC) receiving systemic therapy: Results from the Australian MoST and CaSP screening programs.
ascopubs.org

A pilot single-arm, pragmatic trial in progress of in-home versus in-clinic subcutaneous nivolumab administration through Cancer Care (connected access and remote expertise ...

DIPCAN, a multidimensional approach to precision oncology: Harnessing genomic, clinical, pathological and radiographic data to advance personalized cancer treatment. This is an ASCO Meeting Abstract ...
The American Journal of Managed Care

Review Identifies Top Prognostic Factors in Third-Line or Later DLBCL

Key prognostic factors for DLBCL include early failure on chemo-immunotherapy, performance status, and treatment history. Single-arm trials expedite treatment availability but require external ...
FierceBiotech

FDA steers cancer CAR-T developers toward randomized superiority trials in policy shift

The FDA is raising the bar for approval of CAR T-cell therapies in oncology. Under plans outlined by the FDA’s biologics chief Vinay Prasad, M.D., the agency will require developers of many CAR-Ts to ...